Clinical Trial

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-01; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2025-12-18
Trial Details
NCT Number NCT07260708
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions Advanced Cancers
Enrollment 42 participants
Start Date 2025-12-16
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-21